Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingtong Lin

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The EMBO Journal|March 19, 2021
Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodiesXiancai Ma, Tao Chen, Zhilin Peng, et al.
Molecular Therapy Oncolytics|August 18, 2023
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatmentBaijin Xia, Keming Lin, Xuemei Wang, et al.
Journal of Virology|July 31, 2024
ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latencyMo Zhou, Tao Yang, Ming Yuan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 1, 2023
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 SublineagesXiantao Zhang, Shijian Wu, Jie Liu, et al.
The Journal of Clinical Investigation|August 10, 2021
Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1Bingfeng Liu, Wanying Zhang, Baijin Xia, et al.
EMBO Reports|June 1, 2022
CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2Liyang Wu, Ting Pan, Mo Zhou, et al.
Cell Reports|January 6, 2022
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Yaochang Yuan, Xiantao Zhang, Ran Chen, et al.
Immunity|December 4, 2020
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune ResponsesXiancai Ma, Fan Zou, Fei Yu, et al.
Frontiers in Microbiology|May 16, 2022
Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin LFei Yu, Ting Pan, Feng Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 10, 2022
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other VariantsRan Chen, Xiantao Zhang, Yaochang Yuan, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The EMBO Journal|March 19, 2021
Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodiesXiancai Ma, Tao Chen, Zhilin Peng, et al.
Molecular Therapy Oncolytics|August 18, 2023
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatmentBaijin Xia, Keming Lin, Xuemei Wang, et al.
Journal of Virology|July 31, 2024
ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latencyMo Zhou, Tao Yang, Ming Yuan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 1, 2023
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 SublineagesXiantao Zhang, Shijian Wu, Jie Liu, et al.
The Journal of Clinical Investigation|August 10, 2021
Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1Bingfeng Liu, Wanying Zhang, Baijin Xia, et al.
EMBO Reports|June 1, 2022
CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2Liyang Wu, Ting Pan, Mo Zhou, et al.
Cell Reports|January 6, 2022
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Yaochang Yuan, Xiantao Zhang, Ran Chen, et al.
Immunity|December 4, 2020
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune ResponsesXiancai Ma, Fan Zou, Fei Yu, et al.
Frontiers in Microbiology|May 16, 2022
Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin LFei Yu, Ting Pan, Feng Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 10, 2022
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other VariantsRan Chen, Xiantao Zhang, Yaochang Yuan, et al.
Pageof 4